Renata PLC (DSE:RENATA)

Market Cap	49.68B -25.3%
Revenue (ttm)	44.26B +10.9%
Net Income	2.54B -14.2%
EPS	22.11 -14.2%
Shares Out	114.70M
PE Ratio	19.59
Forward PE	14.58
Dividend	5.50 (1.28%)
Ex-Dividend Date	Nov 18, 2025

Volume	43,129
Average Volume	54,864
Open	430.20
Previous Close	430.30
Day's Range	424.50 - 434.90
52-Week Range	372.00 - 548.00
Beta	-0.09
RSI	44.44
Earnings Date	Apr 28, 2026

About Renata

Renata PLC manufactures, markets, and distributes pharmaceuticals, animal health medicines, oncology-based, agro-based, poultry, and consumer products in Bangladesh. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to reduce toxicity in pedia...

• Industry: Pharmaceutical Preparations
• Founded: 1972
• Employees: 8,366
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: RENATA

Financial Performance

In fiscal year 2025, Renata's revenue was 42.89 billion, an increase of 13.74% compared to the previous year's 37.71 billion. Earnings were 2.22 billion, a decrease of -38.58%.